Core Viewpoint - Corvus Pharmaceuticals, Inc. has announced an upsized underwritten public offering of 7,900,677 shares at a price of $22.15 per share, aiming to raise approximately $175.0 million in gross proceeds before expenses [1][2]. Group 1: Offering Details - The offering includes a 30-day option for underwriters to purchase an additional 1,185,101 shares at the public offering price [1]. - The expected closing date for the offering is around January 23, 2026, pending customary closing conditions [2]. Group 2: Use of Proceeds - The net proceeds from the offering are intended for working capital and general corporate purposes, which may encompass capital expenditures and research and development for various clinical trials, including Phase 3 T cell lymphoma and Phase 2 trials for atopic dermatitis, hidradenitis suppurativa, and asthma [2]. Group 3: Underwriters - Jefferies and Goldman Sachs & Co. LLC are serving as lead book-running managers for the offering, with Mizuho as the bookrunner and Ladenburg Thalmann & Co. Inc. as a co-manager [3]. Group 4: Company Overview - Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing ITK inhibition as a novel immunotherapy approach for various immune diseases and cancers. The lead product candidate is soquelitinib, currently in a Phase 3 trial for relapsed/refractory PTCL and a Phase 1 trial for atopic dermatitis [6].

Core Viewpoint - BioAge Labs, Inc. has announced the pricing of its upsized underwritten public offering of 5,897,435 shares at $19.50 per share, aiming to raise approximately $115.0 million before expenses [1]. Group 1: Offering Details - The offering is expected to close on or about January 23, 2026, subject to customary closing conditions [1]. - BioAge has granted underwriters a 30-day option to purchase an additional 884,615 shares [1]. - Goldman Sachs & Co. LLC, Piper Sandler, and Citigroup are acting as joint book-running managers for the offering [2]. Group 2: Use of Proceeds - The net proceeds will be used to fund research, clinical and process development, and manufacturing of product candidates, including BGE-102, as well as working capital, capital expenditures, and reduction of indebtedness [3]. Group 3: Company Overview - BioAge is a clinical-stage biopharmaceutical company focused on developing therapeutic candidates for metabolic diseases by targeting human aging biology [6]. - The lead product candidate, BGE-102, is a small-molecule NLRP3 inhibitor for cardiovascular risk and retinal diseases, with a Phase 1 trial currently underway [6].

Core Insights - The stock market has seen significant declines among several companies, particularly Venus Concept Inc., IO Biotech, Inc., and Innovation Beverage Group Limited, with notable shifts in their stock values [1] Company Summaries Venus Concept Inc. (VERO) - The company experienced a 56.4% drop in stock price to $1.94, down from a year high of $14.5 to a low of $1.39 [2] - Challenges affecting investor confidence include the decision to voluntarily delist from the Nasdaq Capital Market and deregister with the SEC [2] IO Biotech, Inc. (IOBT) - IO Biotech's stock price decreased by 55.39% to $0.23, falling from a year high of $2.79 to a low of $0.20 [3] - The company focuses on immune-modulating cancer therapies and is exploring strategic alternatives, including a merger or potential liquidation, to enhance stockholder value [3] Innovation Beverage Group Limited (IBG) - The stock price of Innovation Beverage Group fell by 36.67% to $0.98, down from a year high of $9.85 to a low of $0.85 [4] - The company is pursuing energy expansion efforts and a proposed merger with BlockFuel Energy, aiming to advance its integrated energy and infrastructure strategy [4] Market Overview - The significant price movements of these companies highlight the volatile nature of the stock market and the various factors influencing investor sentiment and company valuations [5]

- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today voted in favor of the proposals required to complete the transactions announced in November, including the consummation of the PIPE financing and the related Daewoong note exchange - IRVINE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmace ...

CONSHOHOCKEN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted an equity award on January 15, 2026 to Rita Thakkar, the company’s new Chief Accounting Officer, as an equity inducement award under the terms of Madrigal’s 2025 Inducement Plan. The equity award was approved by Madrigal’s Board of Directors in accord ...

Conference Call and Webcast Scheduled for Wednesday, February 11 SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth quarter and year-end 2025 financial results conference call and webcast for 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time) on February 11, 2026. The schedule for the press release and conference call / webcast is as follows: Q4 and Year-End 2025 Press Release: February 11, 2026 at 1:00 p.m. PT / 4:00 p.m. ET ...

Investors with a lot of money to spend have taken a bearish stance on Corvus Pharma (NASDAQ:CRVS).And retail traders should know.We noticed this today when the positions showed up on publicly available options history that we track here at Benzinga.Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with CRVS, it often means somebody knows something is about to happen.Today, Benzinga's options scanner spotted 14 options trades for Corvus Pharma.This ...

The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and InnovationTARRYTOWN N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Society) and Regeneron today announced the top 40 finalists in the Regeneron Science Talent Search 2026, America’s oldest and most prestigious science and math competition for high school seniors. Key Takeaways: The Regeneron Science Talent Search 2026 finalists represent 35 schools across 15 states. They a ...

Key Takeaways IBRX surged 17.4% after FDA talks aligned on the regulatory path for Anktiva in papillary NMIBC.ImmunityBio finished the requested analyses and plans an sBLA resubmission within a month, with no new study.IBRX's QUILT-3.032 study (Cohort B) met its endpoint, showing durable clinical efficacy with Anktiva.Shares of ImmunityBio (IBRX) surged 17.4% after it announced a recent face-to-face meeting with senior FDA officials to align on the regulatory path forward for Anktiva in an additional indica ...

PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim initiated by Galderma in the arbitration proceedings related to Ipsen’s termination of the R&D agreement. The ICC Tribunal’s decision confirms Ipsen’s full rights to its clinical stage toxin programs in the aesthetic field. “This decisive ICC ruling supports Ipsen’s leadership position in ne ...